Form 8-K · Current report
Becton Dickinson 8-K, filed Jul 22, 2026
- Filed
- CIK
- 0000010795
- Accession no.
- 0001628280-26-049103
Summary
Michael D. Garrison, executive vice president and president of Becton Dickinson's Medical Essentials and BioPharma Systems segments, has informed the company he intends to retire after more than 20 years, effective Oct. 2. BD said a search is underway for the next president of Medical Essentials, and that BioPharma Systems will report directly to Chairman, CEO and President Thomas E. Polen going forward to streamline the operating model.
Key points
- Garrison will remain in his role through the end of BD's fiscal year to support the transition.
- Garrison joined BD in 2005 and previously served as president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery.
- Polen credited Garrison with guiding the company through periods of transformation and developing leaders.
- BD furnished the announcement as a press release attached as Exhibit 99.1 to its Form 8-K.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr. Garrison will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Going forward, to streamline BD's operating model, the BioPharma Systems segment will report directly to Thomas E. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.